A Clinical Trial Assessing Safety of MF101 for Hot Flushes

A Phase 1 Open Label, Randomized Clinical Trial Assessing Safety of MF101 for Hot Flushes and Menopausal Symptoms in Postmenopausal Women

This Phase 1, open label, randomized clinical trial will enroll 40 generally healthy, postmenopausal women aged 40-65 years old. Women will be randomized to one of two oral doses of MF101 for 4 weeks. Participants will be recruited at 3 clinical sites in the United States.

MF101 is an oral, non-hormonal, botanical agent being investigated for the treatment of menopausal hot flashes.

Inclusion Criteria (partial list):

• Postmenopausal women aged 40-65 years.
• Provide informed consent.
• Currently receive medical care from a health care provider. Other inclusions apply.

Exclusion Criteria (partial list):

• History of malignancy other than non-melanoma skin cancer or cervical cancer that was diagnosed and fully treated less than 5 years before screening.
• Unexplained uterine bleeding within 6 months prior to Screening.
• History of deep vein thrombosis or pulmonary embolism.
• Active liver disease or a history of impaired.
• Active gallbladder disease. Other exclusions apply.